Fortress Biotech, Inc.
FBIO · XNASCIK 1429260fmd_08215S0EJ27C9AGWMKTZVNH4WYManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2006 to Sep 30, 2026, 69 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 16 | 17 | 27 | 37 | 46 | 69 | 76 | 85 | 58 | 63 |
| Cost of revenue | 1 | 4 | 6 | 11 | 15 | 32 | 31 | 23 | 21 | 21 |
| Net interest income | – | 0 | 0 | 0 | – | – | – | – | – | – |
| Gross profit | 16 | 14 | 21 | 26 | 31 | 37 | 45 | 62 | 37 | 42 |
| Realized investment gains (losses) | – | – | 2 | – | – | – | – | – | – | – |
| Research and development | 35 | 48 | 87 | 81 | 64 | 129 | 135 | 106 | 57 | 12 |
| Selling, general and administrative | 34 | 51 | 53 | 56 | 61 | 87 | 114 | 91 | 88 | 96 |
| Total operating expenses | 82 | 107 | 147 | – | – | – | – | – | – | – |
| Operating income | (66) | (90) | (120) | (111) | (94) | (189) | (204) | (142) | (110) | (70) |
| Interest expense | 4 | 6 | – | 12 | 15 | 15 | 12 | 15 | 14 | 10 |
| Interest and investment income | 0 | 1 | 1 | 3 | 2 | 1 | 1 | 3 | 3 | 2 |
| Other non-operating income (expense) | (6) | (8) | (11) | 9 | (9) | 24 | (10) | (11) | (10) | 37 |
| Income before taxes | (71) | (98) | (131) | (102) | (103) | (164) | (213) | (154) | (121) | (34) |
| Income tax expense | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | (1) |
| Net income from continuing operations | (71) | (99) | (131) | (102) | (103) | (165) | (214) | (154) | (121) | (33) |
| Net income | (55) | (67) | (84) | (40) | (47) | (65) | (87) | (61) | (46) | 7 |
| Net income to common shareholders | – | – | – | – | – | – | (95) | (69) | (56) | (2) |